TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04419961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants.
Study: NCT02375360

Intervention type: OTHER
Intervention: Oral immunotherapy

Intervention type: OTHER
Intervention: Oral immunotherapy
Study: NCT00320710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to zoledronic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to zoledronic acid
Study: NCT02169271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00414700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
Study: NCT02169271

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT03038542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-framed text messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care text messages
Study: NCT02229760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsules
Study: NCT02627664

Intervention type: OTHER
Intervention: observational study
Description: natural history of non dopaminergic signs
Study: NCT02594293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN alfa-2a
Description: 180 μg/ 0.5 ml ,hypodermic injection once a week
Study: NCT01826331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for Participation
Description: Participants will receive three smoking cessation programs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for Cessation
Description: Participants will have access to a smoking cessation program
Study: NCT01694303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study: NCT01454323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells
Description: Intracoronary infusion of autologous bone marrow-derived mononuclear cells
Study: NCT01694303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Neurobehavioral Intervention
Description: Targeted, computerized interventions completed from the participants' own home on a computer.
Study: NCT04232423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 Mg ORAL TABLET
Description: * Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 Mg ORAL TABLET
Description: * Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 Mg ORAL TABLET
Description: * Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 Mg ORAL TABLET
Description: * Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 Mg ORAL TABLET
Description: * Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 Mg ORAL TABLET
Description: * Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ORAL TABLET
Description: * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ORAL TABLET
Description: * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ORAL TABLET
Description: * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4
Study: NCT04294368

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid
Description: The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Similac Liquid Protein Fortifier
Description: For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nestle Microlipid
Description: For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
Study: NCT02415959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon IR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon® (DR/GR)
Study: NCT01677455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
Study: NCT04294368

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Medica Nutrition SolCarb
Description: For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)
Description: The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Liquid Protein Fortifier (Targeted Fortification)
Description: Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Microlipid (Targeted Fortification)
Description: Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
Study: NCT00347425

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Olanzapine
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days

Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone
Description: Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
Study: NCT04027673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMW ECE Curriculum
Description: The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
Study: NCT03143634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Modular Protocol for Mental Health
Description: This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment-as-usual
Description: This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
Study: NCT02099968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Modification
Description: * Fasting (1st week), followed by:~* Vegetarian and modified DASH diet (plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation, meditation, yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Modification / modified DASH
Description: * Modified DASH (vegetarian focused, plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation
Study: NCT00200395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
Study: NCT02791659

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Automatic beam adjustment function
Description: The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Automatic beam adjustment function
Description: The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
Study: NCT01881399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence cholangiography (da Vinci surgical system)
Description: Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual cholangiography
Description: Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional IOC
Description: Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
Study: NCT01953159

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Patient Questionnaires

Intervention type: OTHER
Intervention: Patient Questionnaires
Study: NCT00077428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01410383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome
Description: Tablets taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprotirome
Description: Tablets taken daily
Study: NCT03534297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapansutrile capsules
Description: Hard opaque capsules containing 100 mg of API.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Hard opaque capsules containing 0 mg of API.
Study: NCT01033383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Capsule
Description: 36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Capsule
Description: 36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Capsule
Description: 36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
Study: NCT02139683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: HIFU treatment in patients with fibroadenoma
Study: NCT01815021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amorphous calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: crystalline calcium supplements
Study: NCT00106028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium (Actonel)
Description: risedronate tablet once a day for one year followed by risedronate once a day for two years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once a day for one year followed by risedronate once a day for two years
Study: NCT04479657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QingFei Granule
Description: QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: 30mg/kg/d,bid, used until to the normalization of blood routine。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Description: 30mg/kg/d,bid, used until to the normalization of blood routine。
Study: NCT02739815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline containing a prophylactic Antibiotic 1 g
Description: 500 ml of normal saline containing a prophylactic Antibiotic 1 g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline containing a prophylactic Antibiotic 1 g
Description: 500 ml of normal saline containing a prophylactic Antibiotic 1 g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline containing a prophylactic Antibiotic 1 g
Description: 500 ml of normal saline containing a prophylactic Antibiotic 1 g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline containing a prophylactic Antibiotic 1 g
Description: 500 ml of normal saline containing a prophylactic Antibiotic 1 g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid
Study: NCT03564925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide area circumferential ablation
Description: Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
Study: NCT00058357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01810926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: polyclonal antibody
Description: iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: polyclonal antibody
Description: iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: polyclonal antibody
Description: iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: single infusion of200 mg/m2 on day -1

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Treosulfan
Description: iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Treosulfan
Description: iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fludarabine
Description: iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan